#USA #New York #Drug Development #Novellia #RWD

Novellia Secures 2026 Fierce Outsourcing Award

On April 14, 2026, Novellia made headlines by winning the prestigious 2026 Fierce Outsourcing Award for its groundbreaking contributions to drug development. The accolade, presented by Fierce Pharma, highlights the company’s innovative approach in utilizing real-world data (RWD), a transformative element in biopharma research. This recognition positions Novellia at the forefront of advancing medical science, showcasing its commitment to revolutionizing how drugs are discovered and developed.

A Unique Concept in Real-World Data

Novellia stands out in the medical research field as the only real-world data company that operates solely on the information that patients voluntarily contribute. Traditional models often rely on fragmented data sources gathered from third-party brokers, which can lead to inaccuracies and inefficiencies. By contrast, Novellia's platform empowers patients to unify their medical histories—spanning over 20 years—into a cohesive narrative that can significantly inform treatment plans and research initiatives.

Shashi Shankar, Co-founder and CEO of Novellia, emphasized the importance of trust in patient data. He noted that “the breakthroughs coming in medicine will be built on patient trust,” which has traditionally been overlooked. Novellia aims to bridge that gap by ensuring patients are involved in the data sharing process, thus enriching the research landscape with valuable insights.

How the Platform Works

The Novellia platform utilizes advanced artificial intelligence (AI) to help patients effortlessly gather their medical records from various healthcare providers. In a matter of seconds, patients facing complex health challenges can obtain a comprehensive view of their care history. This capability not only enhances their understanding of personal healthcare journeys but also offers researchers previously unattainable insights into real-life health outcomes.

When these anonymized and harmonized datasets are shared with pharmaceutical companies, they fuel the development of new treatments and cures. Notably, Novellia has already partnered with several top pharmaceutical firms, demonstrating the practical impact of their data-driven approach.

The Significance of the Award

Receiving the Fierce Outsourcing Award signifies not only recognition of Novellia's innovative platform but also highlights a critical shift in how pharmaceutical researchers will approach drug development moving forward. By placing patient-derived data at the forefront, the industry may see a reduction in the estimated $50 billion wasted annually due to inefficient data use. With patient input now considered a vital element of the research process, the quality and efficacy of new treatments can be significantly improved.

Celebrating the Achievement

The winners of the Fierce Outsourcing Awards will be celebrated during the upcoming Fierce Biotech Week, which is set for May 13. This event gathers industry leaders, innovators, and stakeholders to discuss significant advances in pharmaceutical development and research partnerships—a fitting backdrop for Novellia’s momentous achievement.

Looking Ahead

As Novellia continues to grow and pave the way for the use of patient data in scientific research, the impact of this award will likely resonate through the industry. By fostering a culture of collaboration and trust between patients and researchers, Novellia is on a mission to transform not just drug development, but the entire healthcare landscape.

In summary, Novellia’s recognition at the 2026 Fierce Outsourcing Awards not only highlights the company's unique approach to real-world data but also serves as a pivotal moment in the quest for more effective and patient-centered medical treatments. As the company continues to innovate, the future of drug development looks promising, driven by the voices and experiences of the patients themselves.